- Home
- SHLS vs ZYME Comparison
SHLS vs ZYME Comparison
Compare SHLS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHLS
- ZYME
- Stock Information
- Founded
- SHLS 1996
- ZYME 2003
- Country
- SHLS United States
- ZYME United States
- Employees
- SHLS N/A
- ZYME N/A
- Industry
- SHLS Semiconductors
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- SHLS Technology
- ZYME Health Care
- Exchange
- SHLS Nasdaq
- ZYME Nasdaq
- Market Cap
- SHLS 845.2M
- ZYME 751.6M
- IPO Year
- SHLS 2021
- ZYME 2017
- Fundamental
- Price
- SHLS $5.03
- ZYME $13.23
- Analyst Decision
- SHLS Buy
- ZYME Buy
- Analyst Count
- SHLS 21
- ZYME 6
- Target Price
- SHLS $10.60
- ZYME $18.83
- AVG Volume (30 Days)
- SHLS 4.6M
- ZYME 416.1K
- Earning Date
- SHLS 11-12-2024
- ZYME 10-31-2024
- Dividend Yield
- SHLS N/A
- ZYME N/A
- EPS Growth
- SHLS N/A
- ZYME N/A
- EPS
- SHLS 0.19
- ZYME N/A
- Revenue
- SHLS $422,657,000.00
- ZYME $62,199,000.00
- Revenue This Year
- SHLS N/A
- ZYME $21.53
- Revenue Next Year
- SHLS $11.57
- ZYME N/A
- P/E Ratio
- SHLS $25.42
- ZYME N/A
- Revenue Growth
- SHLS N/A
- ZYME N/A
- 52 Week Low
- SHLS $4.07
- ZYME $7.97
- 52 Week High
- SHLS $17.50
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- SHLS 52.36
- ZYME 42.19
- Support Level
- SHLS $4.14
- ZYME $12.43
- Resistance Level
- SHLS $4.72
- ZYME $14.10
- Average True Range (ATR)
- SHLS 0.30
- ZYME 0.63
- MACD
- SHLS 0.03
- ZYME -0.10
- Stochastic Oscillator
- SHLS 63.49
- ZYME 26.50
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.